The civic record

Read. Follow. Verify.

FEDERALlobbying filing

Lobbying Disclosure: ACG Advocacy for AbbVie (Q2 2026)

Original title: ACG Advocacy → AbbVie (2nd Quarter Report 2026)

Record date · July 20, 2026

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Does

This document is a federal report detailing the activities and income of ACG Advocacy on behalf of their client, AbbVie, during the second quarter of 2026. The firm reported $60,000 in income for lobbying services related to trade policy and patent legislation.

Why it matters

This filing provides transparency regarding the financial investment and specific policy interests of AbbVie as they seek to influence federal trade and patent regulations.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

AbbVie

The company is the client paying for lobbying services to influence federal trade and patent policy.

Directly affected

ACG Advocacy

The firm is the registrant responsible for reporting its lobbying activities and income to the federal government.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What is the purpose of this document?

This is a mandatory federal disclosure report that tracks lobbying activity and payments to ensure transparency in how private entities interact with government officials.

How much did AbbVie spend on this specific lobbying effort?

The document reports that ACG Advocacy received $60,000 from AbbVie for lobbying services during the second quarter of 2026.

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Follow the record

Votes, people, money & the original source

Lobbying Activity

ACG Advocacy

on behalf of AbbVie

2026

TRADE (DOMESTIC/FOREIGN)COPYRIGHT/PATENT/TRADEMARK

“Trade Policy.”

Senate LDAMatched on title words onlyView filing on LDA.gov →

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

financial connection90% confidence

Pharmaceutical Lobbying Focus

The document highlights a clear focus on patent review procedures and trade policy, which are critical regulatory areas for pharmaceutical companies like AbbVie.

AbbVie Patent & Trademark Office

Connected Entities

Executive Office of the President, U.S. Trade Representative, Manus Cooney and 10 more

OrganizationExecutive Office of the President“Agency lobbied regarding trade policy.”Map →

OrganizationU.S. Trade Representative“Agency lobbied regarding trade policy.”Map →

PersonManus Cooney“Lobbyist for ACG Advocacy.”Map →

OrganizationACG Advocacy“The lobbying firm filing the report.”Map →

OrganizationU.S. Senate“Agency lobbied regarding patent legislation.”Map →

OrganizationTreasury - Dept of“Agency lobbied regarding trade policy.”Map →

PersonCameron Seward“Lobbyist for ACG Advocacy.”Map →

PersonChris Israel“Lobbyist for ACG Advocacy.”Map →

OrganizationPatent & Trademark Office“Agency lobbied regarding patent review procedures.”Map →

OrganizationCommerce - Dept of“Agency lobbied regarding trade policy.”Map →

OrganizationU.S. House of Representatives“Agency lobbied regarding patent legislation.”Map →

OrganizationAbbVie“The client paying for lobbying services.”Map →

PersonDana Colarulli“Lobbyist for ACG Advocacy.”Map →

Sources

Open source document

lda.gov

Analysis Score

0–100

Significance40
How much this matters to a regular citizen
Controversy20
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz10
Current news / social attention level

Publisher tools